News | News By Subject | News by Disease News By Date | Search News

Sarcoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
CytRx (CYTR) Plans to File NDA for Once-Failed Sarcoma Drug While Columnist Raises Questions Over Efficacy and CEO Salary Amid Struggle     11/30/2016
FDA Hits Adaptimmune (ADAP) with a Partial Hold on Pivotal Sarcoma Trial, Stock Tanks     8/4/2016
CytRx (CYTR) Craters After Aldoxorubicin Flops in Phase III Trial     7/12/2016
3 Biotechs Getting Another Shot After Failed Trials     4/7/2016
GlaxoSmithKline (GSK) Kills U.S. Part of Eczema Treatment Deal With Basilea (BSLN.SW)     1/22/2016
Threshold Pharma (THLD) Crumbles as Merck KGaA (MKGAF.PK) Abandons Cancer Drug After Trial Failures     12/7/2015
EXCLUSIVE: Navidea (NAVB) CEO Tells BioSpace (DHX) New Cancer Treatment Will See More Trial Data in 2015     4/29/2015
FDA Removes Partial Clinical Hold on CytRx Corporation (CYTR)'s Brain Cancer Trials     1/21/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
FDA Puts Partial Hold On CytRx Corporation (CYTR)'s Aldoxorubicin Clinical Trials     11/19/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
SSF's Threshold Pharmaceuticals, Inc. (THLD) Snags Fast Track Status For Experimental Cancer Drug TH-302     11/11/2014
CytRx Corporation (CYTR) Soars As Cancer Drug Meets Main Goal In Phase 2 Study     12/12/2013
ZIOPHARM Oncology, Inc. (ZIOP.OB)'s Treatment for Soft Tissue Sarcoma Meets Study Goals     2/12/2013
Eisai Company, Ltd. (ESALY.PK)'s Farletuzumab Fails Ovarian Cancer Trial     1/15/2013

News from Around the Web

Press Releases
CytRx (CYTR) Reports Statistically Significant Updated Results From Pivotal Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcomas     11/29/2016
Arog Pharmaceuticals Receives Orphan Drug Designation In The European Union For Crenolanib For The Treatment Of Acute Myeloid Leukemia And Soft Tissue Sarcoma     11/22/2016
CytRx (CYTR) Presents Positive Interim Results From On-Going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting     11/14/2016
TRACON Pharma (TCON) Announces Presentation Of Updated Data From Phase Ib/II Study Of TRC105 And Votrient In Patients With Angiosarcoma     11/11/2016
Philogen S.p.A. Receives Orphan Drug Designation For The Treatment Of Soft Tissue Sarcoma     10/28/2016
FDA Approves Eli Lilly (LLY)'s LARTRUVO (Olaratumab) In Combination With Doxorubicin For Soft Tissue Sarcoma     10/20/2016
CytRx (CYTR) Presents Interim Results From On-Going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress     10/10/2016
TRACON Pharma (TCON) Announces Successful Meetings With FDA And EMA For TRC105 (Carotuximab) In Angiosarcoma     10/3/2016
CHMP Recommends Approval Of Eli Lilly (LLY)'s Olaratumab, In Combination With Doxorubicin, For Advanced Soft Tissue Sarcoma     9/16/2016
Oncternal Therapeutics Initiates Patient Dosing In Phase 1 Clinical Trial Of TK216 In Ewing Sarcoma     8/30/2016
Adaptimmune (ADAP) Receives Access To Priority Medicines (PRIME) Regulatory Support For Its SPEAR T-Cell Therapy Targeting NY-ESO For Treatment Of Soft Tissue Sarcoma     7/28/2016
Karyopharm (KPTI) Announces Phase Ib Selinexor Sarcoma Data Published In Journal Of Clinical Oncology     7/27/2016
Adaptimmune (ADAP) Receives Orphan Drug Designation In The European Union For Its NY-ESO SPEAR T-Cell Therapy For Treatment Of Soft Tissue Sarcoma     7/26/2016
Gradalis Inc. Appoints Martin J. Birkhofer, M.D. Chief Medical Officer     7/26/2016
Mevion Medical Systems Release: First Cancer Patient In Ohio Receives Proton Therapy Treatment     7/26/2016

//-->